SC
JANX icon

Stephens Consulting’s Janux Therapeutics JANX Stock Holding History

Stephens Consulting’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$405 – 1586
2025
Q1 		$405 Buy
+15
New +$565 ﹤0.01% 1032

Other funds holding JANX

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Stephens Consulting's JANX Position: Q2 2025 in Review

Stephens Consulting sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 15 shares — an estimated $405 sold.

Stephens Consulting first reported a position in JANX in Q1 2025 and held it in 1 quarter. The position peaked at $405 in Q1 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • Stephens Consulting reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 15 Janux Therapeutics shares in Q2 2025, an estimated $405.
  • Stephens Consulting first reported a position in Janux Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Janux Therapeutics position peaked at $405 in Q1 2025.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.